All lobbying filings

Miller Strategies, LLC

Miller Strategies, LLC filed a Q2 report for Ultragenyx Pharmaceutical Inc. on July 20, 2026, reporting $140,000 in lobbying income.

Lobbying for Ultragenyx Pharmaceutical Inc. · Biopharmaceutical company focused on developing novel therapies for rare genetic diseases

As filed: MILLER STRATEGIES, LLC for ULTRAGENYX PHARMACEUTICAL INC.

All filings by Miller Strategies, LLC · Everything Ultragenyx Pharmaceutical Inc. has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$140,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medical/Disease Research/Clinical Labs

Issues relating to rare disease and patient access.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.